|
1
|
Houtkooper RH, Pirinen E and Auwerx J:
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol
Cell Biol. 13:225–238. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kiran S, Anwar T, Kiran M and Ramakrishna
G: Sirtuin 7 in cell proliferation, stress and disease. Rise of the
Seventh Sirtuin! Cell Signal. 27:673–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
North BJ and Verdin E: Sirtuins:
Sir2-related NAD-dependent protein deacetylases. Genome Biol.
5:2242004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haigis MC and Sinclair DA: Mammalian
sirtuins: Biological insights and disease relevance. Ann Rev
Pathol. 5:253–295. 2010. View Article : Google Scholar
|
|
5
|
Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu
S, Hu Y and Cai T: Sirt7 promotes gastric cancer growth and
inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep.
5:2015.
|
|
6
|
Grob A, Roussel P, Wright JE, McStay B,
Hernandez-Verdun D and Sirri V: Involvement of SIRT7 in resumption
of rDNA transcription at the exit from mitosis. J Cell Sci.
122:489–498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshizawa T, Karim MF, Sato Y, Senokuchi
T, Miyata K, Fukuda T, Go C, Tasaki M, Uchimura K, Kadomatsu T, et
al: SIRT7 controls hepatic lipid metabolism by regulating the
ubiquitin-proteasome pathway. Cell Metab. 19:712–721. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ,
Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geng Q, Peng H, Chen F, Luo R and Li R:
High expression of Sirt7 served as a predictor of adverse outcome
in breast cancer. Int J Clin Exp Pathol. 8:1938–1945.
2015.PubMed/NCBI
|
|
10
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. New Eng J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, McKay RM and Parada LF: Malignant
glioma: Lessons from genomics, mouse models, and stem cells. Cell.
149:36–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aldape K, Zadeh G, Mansouri S,
Reifenberger G and von Deimling A: Glioblastoma: Pathology,
molecular mechanisms and markers. Acta Neuropathol. 129:829–848.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eckert A, Böck BC, Tagscherer KE, Haas TL,
Grund K, Sykora J, Herold-Mende C, Ehemann V, Hollstein M,
Chneiweiss H, et al: The PEA-15/PED protein protects glioblastoma
cells from glucose deprivation-induced apoptosis via the ERK/MAP
kinase pathway. Oncogene. 27:1155–1166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeigler ME, Chi Y, Schmidt T and Varani J:
Role of ERK and JNK pathways in regulating cell motility and matrix
metalloproteinase 9 production in growth factor-stimulated human
epidermal keratinocytes. J Cell Physiol. 180:271–284. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levy DE and Darnell JE Jr: Stats:
Transcriptional control and biological impact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iwamaru A, Szymanski S, Iwado E, Aoki H,
Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A
novel inhibitor of the STAT3 pathway induces apoptosis in malignant
glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re3532016. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai Z, Wu J, Chen F, Cheng Q, Zhang M,
Wang Y, Guo Y and Song T: CXCL5 promotes the proliferation and
migration of glioma cells in autocrine- and paracrine-dependent
manners. Oncol Rep. 36:3303–3310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu T, Liu PY and Marshall GM: The
critical role of the class III histone deacetylase SIRT1 in cancer.
Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ford E, Voit R, Liszt G, Magin C, Grummt I
and Guarente L: Mammalian Sir2 homolog SIRT7 is an activator of RNA
polymerase I transcription. Genes Dev. 20:1075–1080. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ashraf N, Zino S, Macintyre A, Kingsmore
D, Payne AP, George WD and Shiels PG: Altered sirtuin expression is
associated with node-positive breast cancer. Br J Cancer.
95:1056–1061. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Longo VD and Kennedy BK: Sirtuins in aging
and age-related disease. Cell. 126:257–268. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mansour SJ, Matten WT, Hermann AS, Candia
JM, Rong S, Fukasawa K, Vande Woude GF and Ahn NG: Transformation
of mammalian cells by constitutively active MAP kinase kinase.
Science. 265:966–970. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen D, Zuo D, Luan C, Liu M, Na M, Ran L,
Sun Y, Persson A, Englund E, Salford LG, et al: Glioma cell
proliferation controlled by ERK activity-dependent surface
expression of PDGFRA. PLoS One. 9:e872812014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Guo Q, Wang R, Xu G, Li P, Sun Y,
She X, Liu Q, Chen Q, Yu Z, et al: The D Domain of LRRC4 anchors
ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK
activation in glioma cells. J Hematol Oncol. 9:1302016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Glassmann A, Reichmann K, Scheffler B,
Glas M, Veit N and Probstmeier R: Pharmacological targeting of the
constitutively activated MEK/MAPK-dependent signaling pathway in
glioma cells inhibits cell proliferation and migration. Int J
Oncol. 39:1567–1575. 2011.PubMed/NCBI
|
|
30
|
Lin F, Chengyao X, Qingchang L, Qianze D,
Enhua W and Yan W: CRKL promotes lung cancer cell invasion through
ERK-MMP9 pathway. Mol Carcinog. 54:E35–E44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Justicia C, Gabriel C and Planas AM:
Activation of the JAK/STAT pathway following transient focal
cerebral ischemia: Signaling through Jak1 and Stat3 in astrocytes.
Glia. 30:253–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dasgupta A, Raychaudhuri B, Haqqi T,
Prayson R, Van Meir EG, Vogelbaum M and Haque SJ: Stat3 activation
is required for the growth of U87 cell-derived tumours in mice. Eur
J Cancer. 45:677–684. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sherry MM, Reeves A, Wu JK and Cochran BH:
STAT3 is required for proliferation and maintenance of multipotency
in glioblastoma stem cells. Stem cells. 27:2383–2392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
